Clinical trial
Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies (LYMPHCORD)
Overall survival at one year. Efficacy >60%, rejection rate <20%. inclusion criteria: age: 18-65 years old, no sibling or unrelated donor identified, low grade non-hodgkin lymphoma in third line (who already received at least one autologous transplantation); hodgkin lymphoma in early relapse (><1 year), who received at least one autologous transplantation and sensible to chemotherapy and cll with 17p deletion or in relapse less than 2 year after a fludarabine nbased regimen or in relapse after one autologous transplantation.>
1>20%.>
Category | Value |
---|---|
Study start date | 2013-10-17 |